Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an
effective method for treating cancer. All patients will receive binimetinib at a standard
dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I
studies. Eligible subjects will have lung cancer that has a mutation in a key cancer gene
called KRAS, and the cancer has spread to other parts of their body.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania